Updated:
Accumen Inc.
Accumen Inc. (hc1) delivers an AI-powered lab intelligence platform for health systems, processing 30B+ clinical transactions. Founded 2011.
Accumen Inc.
Accumen Inc., doing business as hc1, was founded in 2011 by a team that saw health system laboratories as underutilized sources of clinical and operational intelligence (per the firm). The company is headquartered in San Diego, United States, and has grown through a combination of organic product development and strategic acquisition. The firm's platform, hc1 IQ™, comprises four solution suites: Clinical IQ™ for care gap detection and test utilization, Ops IQ™ for lab workflow optimization, Source IQ™ for supply chain and contract intelligence, and Signal IQ™ for market growth and churn analysis. Accumen serves over 450 hospitals and health systems, processing data from more than 90 million unique patients and 30 billion clinical transactions (per hc1, 2026). The firm expanded into life sciences by matching patient needs with therapies using lab, EHR, and claims data. Its geographic footprint is primarily the United States. In 2021, hc1 acquired Accumen, a lab performance consulting firm, completing what the company describes as the most comprehensive end-to-end partner for health system lab transformation (per hc1, 2026). The firm launched the hc1 IQ™ platform in 2022. It also maintains a blog and a racing sponsorship under hc1 Racing, though no philanthropic foundation or additional investment vehicles are publicly named. Accumen's structural differentiator is its single-platform approach to lab intelligence — unifying clinical, operational, supply chain, and growth functions that are typically handled by separate vendors. This integrated model allows health systems to measure ROI enterprise-wide, rather than in isolated silos.
General information
Firm type
Asset Manager
Year founded
2011
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Accumen Inc.?
Accumen does not publicly disclose its executive leadership or investment committee, though the firm's website lists a 'Team' page that was not retrievable in this analysis. The firm operates as a technology and consulting company, not a traditional investment vehicle.
Is Accumen structured as a single family office or a technology firm?
Accumen Inc. is structured as a technology company that develops and sells AI-powered software to health systems. It operates under the brand hc1 and does not present itself as a family office or asset manager.
How does Accumen source proprietary deal flow?
Accumen does not source deal flow in the traditional investment sense. The firm acquired Accumen in 2021 to add consulting expertise, but it primarily grows through direct sales of its hc1 IQ™ platform to hospitals and health systems.
Does Accumen participate in fund commitments or only direct deals?
Accumen does not appear to participate in fund commitments. It is a commercial enterprise selling software and consulting services, not an investment fund manager.
What investment stages does Accumen typically target?
Accumen does not target investment stages. It is a product and services company serving health systems of varying sizes, from hospitals to large integrated health networks.
Where does the underlying wealth come from?
Accumen's wealth origin is not publicly disclosed. The firm is a private company with no known family-office affiliation.
Does Accumen maintain philanthropic structures, and how are they separated?
There is no public record of a philanthropic foundation or separate charitable arm associated with Accumen. The firm's corporate website does not mention any philanthropic structures.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: